| Argosy Minerals Limited (AGY) ORDINARY FULLY PAID |
Materials |
$39 |
Trading Halt
|
31 Aug 2026 9:19AM |
$0.043 |
$0.024 |
fallen by
44.19%
|
|
AGY - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Argosy Minerals Limited (ASX: AGY) into a trading halt on 31 August 2026.
- The trading halt was requested by AGY pending a market announcement.
- The pending announcement relates to a capital raising.
- Unless ASX decides otherwise, the halt will remain until the earlier of the announcement being released or normal trading commencing on Wednesday, 2 September 2026.
- The request was made under ASX Listing Rule 17.1.
- AGY stated it was not aware of any reason why the trading halt should not be granted.
- The request was authorised by Andrea Betti, Non-Executive Director and Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,218 |
Update - Notification of buy-back - AFI
|
31 Aug 2026 9:18AM |
$6.910 |
$6.700 |
fallen by
3.04%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$774 |
Update - Notification of buy-back - DJW
|
31 Aug 2026 9:18AM |
$3.000 |
$2.970 |
fallen by
1%
|
|
| Ryman Healthcare Limited (RYM) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$1,488 |
Ryman Healthcare Limited - Capital Change Notice
|
31 Aug 2026 9:18AM |
$1.770 |
$1.465 |
fallen by
17.23%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$280 |
Update - Notification of buy-back - AMH
|
31 Aug 2026 9:18AM |
$0.910 |
$0.890 |
fallen by
2.20%
|
|
| Andean Silver Limited (ASL) ORDINARY FULLY PAID |
Materials |
$358 |
Trading Halt
|
31 Aug 2026 9:17AM |
$2.840 |
$1.555 |
fallen by
45.25%
|
|
ASL - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Andean Silver Limited (ASX: ASL) into a trading halt at the company’s request.
- The trading halt was requested pending an announcement about a capital raising.
- The halt was to remain in place until the earlier of the announcement being released or the commencement of normal trading on Wednesday, 2 September 2026.
- The request was made under ASX Listing Rule 17.1.
- Andean Silver stated it was not aware of any other information necessary to inform the market about the trading halt.
- Andean Silver stated it was not aware of any reason why the trading halt should not be granted.
- The request was authorised by the Board of Andean Silver Limited and signed by Company Secretary Maddison Cramer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
2026 Appendix 4G and Corporate Governance Statement
|
31 Aug 2026 9:17AM |
$0.018 |
$0.017 |
fallen by
5.56%
|
|
| Kingsgate Consolidated Limited (KCN) ORDINARY FULLY PAID |
Materials |
$1,260 |
Dividend/Distribution - KCN
|
31 Aug 2026 9:16AM |
$5.310 |
$4.730 |
fallen by
10.92%
|
|
| Centrepoint Alliance Limited (CAF) ORDINARY FULLY PAID |
Financials |
$81 |
Ceasing to be a substantial holder
|
31 Aug 2026 9:16AM |
$0.375 |
$0.385 |
risen by
2.67%
|
|
| Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID |
Health Care |
$54 |
Avecho enters final stage of Phase III insomnia trial
|
31 Aug 2026 9:15AM |
$0.023 |
$0.014 |
fallen by
39.13%
|
|
AVE - Price-sensitive ASX Announcement
Full Release
Key Points
- Avecho has recommenced recruitment for the final stage of its pivotal Phase III insomnia trial.
- The trial is evaluating Avecho’s TPM®-enhanced CBD soft-gel capsule for insomnia.
- Approximately 320 additional participants are expected to be enrolled in the second cohort.
- The study is proceeding to its original planned size of 519 participants completing the trial.
- The decision follows a positive interim analysis announced in June 2026.
- The independent Data Monitoring Board unanimously recommended continuing the trial without increasing sample size.
- Interim analysis data covered 244 participants.
- No serious adverse events were identified in the interim safety review.
- The trial is multi-centre, randomised, double-blind and placebo-controlled.
- Participants receive nightly doses of 75mg CBD, 150mg CBD or placebo over eight weeks.
- Sleep outcomes are being measured through validated questionnaires and daily sleep diaries.
- Existing sites have resumed recruitment and additional sites will be activated progressively.
- Avecho expects recruitment of the remaining participants to be completed within about 12 months once additional sites are operational.
- Avecho remains blinded to treatment allocations and efficacy results until study completion and final analysis.
- A successful Phase III result would support a TGA submission for pharmaceutical registration of the CBD capsule for insomnia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
FY26 Results Presentation
|
31 Aug 2026 9:15AM |
$0.018 |
$0.017 |
fallen by
5.56%
|
|
| hipages Group Holdings Limited (HPG) ORDINARY FULLY PAID |
Communication Services |
$115 |
Initial Director's Interest Notice - SF
|
31 Aug 2026 9:15AM |
$0.960 |
$0.845 |
fallen by
11.98%
|
|
| Qmines Limited (QML) ORDINARY FULLY PAID |
Materials |
$52 |
High-Grade Copper & Gold Continues at Mt Chalmers
|
31 Aug 2026 9:15AM |
$0.067 |
$0.068 |
risen by
1.49%
|
|
QML - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement dated 31 August 2026.
- QMines Limited reported new drilling results from its 100%-owned Mt Chalmers Copper and Gold Project in Central Queensland.
- Hole 26MCRD006 returned 32m at 1.99% Cu, 0.39g/t Au and 2.6g/t Ag from 138m.
- The copper intersection included 10m at 3.21% Cu, 7m at 4.18% Cu and a peak 1m at 11.3% Cu.
- Gold strengthened toward the base of hole 26MCRD006 with 7m at 2.14% Cu and 1.00g/t Au, including 1m at 5.63g/t Au.
- Hole 26MCDD008 intersected a shallow polymetallic lens grading 25m at 2.08g/t Au, 92g/t Ag, 2.56% Zn and 0.19% Cu from 56m.
- Within that lens, QMines reported 7m at 5.79g/t Au, 147g/t Ag and 5.16% Zn.
- Peak 1m grades in hole 26MCDD008 reached 12.6g/t Au, 260g/t Ag and 10.75% Zn.
- The company said these were the highest gold and silver grades returned so far from the current Mt Chalmers drilling program.
- Results support the interpretation of Mt Chalmers as a VHMS system with deeper copper-gold stringer mineralisation and upper polymetallic massive sulphide lenses.
- Lead and zinc were negligible in 26MCRD006, supporting its interpretation as a copper-dominant feeder zone beneath the massive sulphide system.
- QMines noted silver, lead and zinc grades between 68m and 76m in 26MCDD008 may be understated because of barite interference, with re-assay work underway.
- Mineralisation remains open and ongoing drilling continues to test the broader Mt Chalmers system.
- The announcement said 10 holes were in the laboratory with further assays awaited.
- The drilling program also supports metallurgical, geotechnical and DFS-related studies at Mt Chalmers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| hipages Group Holdings Limited (HPG) ORDINARY FULLY PAID |
Communication Services |
$115 |
Final Director's Interest Notice - NG
|
31 Aug 2026 9:15AM |
$0.960 |
$0.845 |
fallen by
11.98%
|
|
| hipages Group Holdings Limited (HPG) ORDINARY FULLY PAID |
Communication Services |
$115 |
Changes to Board of Directors
|
31 Aug 2026 9:14AM |
$0.960 |
$0.845 |
fallen by
11.98%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$507 |
Weekly NTA 28.08.2026
|
31 Aug 2026 9:13AM |
$2.460 |
$2.280 |
fallen by
7.32%
|
|
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$20 |
Appendix 4G Corporate Governance Statement
|
31 Aug 2026 9:13AM |
$0.150 |
$0.110 |
fallen by
26.67%
|
|
| Verbrec Limited (VBC) ORDINARY FULLY PAID |
Industrials |
$69 |
FY2026 Appendix 4G & Corporate Governance Statement
|
31 Aug 2026 9:13AM |
$0.190 |
$0.225 |
risen by
18.42%
|
|
| Australian Ethical Investment Limited (AEF) ORDINARY FULLY PAID |
Financials |
$475 |
Change in substantial shareholding for AFG
|
31 Aug 2026 9:13AM |
$4.690 |
$4.170 |
fallen by
11.09%
|
|
| Australian Finance Group Ltd (AFG) ORDINARY FULLY PAID |
Financials |
$353 |
Change in substantial shareholding from AEF
|
31 Aug 2026 9:13AM |
$1.575 |
$1.340 |
fallen by
14.92%
|
|
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
2026 Appendix 4E and Annual Report
|
31 Aug 2026 9:13AM |
$0.018 |
$0.017 |
fallen by
5.56%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Reporting period covered the financial year ended 30 June 2026.
- Revenue from ordinary activities increased 41% to $5,333,849.
- Loss after tax attributable to owners improved 29% to $3,513,587.
- Total comprehensive loss attributable to owners improved 30% to $3,423,464.
- Basic and diluted loss per share were both 0.425 cents negative.
- No dividends were paid, recommended or declared.
- Net tangible assets per ordinary security were $0.72, unchanged from the prior year.
- Revenue was mainly from point-of-care tests of $2,840,399 and point-of-care technology of $2,150,773.
- Other income included an R&D tax rebate of $1,260,540 and government grant income of $886,925.
- Gross margin fell from 51% to 35%, mainly because the prior year included one-off licence fees.
- Operating expenses were reduced by more than $781,000, reflecting ongoing cost control.
- Net capital raised during the year was about $4.06 million to fund product portfolio expansion, commercial activity and cost reductions.
- Cash and cash equivalents at 30 June 2026 were $3,708,792, up from $3,219,646 a year earlier.
- Atomo reported no debt and stated the accounts were prepared on a going concern basis.
- The company highlighted momentum in HIV self-testing programs across Europe, Australia and New Zealand.
- Point-of-care technology sales rose strongly, supported by increased Lumos FebriDx-related orders using Atomo’s Pascal device.
- Significant year events included placements and an SPP that expanded issued capital to 902,432,853 ordinary shares.
- Net assets at year end were $7,706,782.
- The financial statements were audited by BDO Audit Pty Ltd and received an unmodified opinion.
- John Kelly resigned as Managing Director on 19 August 2026 and Cheri Walker was appointed Interim Chief Executive Officer.
- Atomo advised its Annual General Meeting is expected to be held on or about 5 November 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$4 |
Hydrix Advancing Strategic Defence Activities
|
31 Aug 2026 9:13AM |
$0.004 |
$0.003 |
fallen by
28.57%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix provided an update on its strategy to advance defence activities and commercialise defence-related intellectual property.
- The company is prioritising opportunities against Australian Defence requirements, technology readiness and sovereign capability objectives.
- Australia’s 2026 National Defence Strategy includes a A$425 billion Integrated Investment Program with A$7 billion allocated to counter-drone and counter-UAS capability.
- Hydrix has started developing and feasibility testing sensing technologies for UAS, counter-UAS and persistent ISR applications.
- Early prototypes are being developed and tested to assess technical performance, market requirements and commercialisation pathways.
- The work draws on Hydrix capabilities in advanced sensing, autonomous systems, AI/ML, mission-critical embedded systems and high-reliability electronics.
- Hydrix is engaging with universities and research organisations to identify world-class technologies with commercial potential, including sensing and Edge AI.
- Potential commercial outcomes include IP licensing, engineering development, industry and Defence trials, and delivery into Australian and international Defence markets.
- Hydrix is expanding defence industry relationships and testing demand through engagement and forums such as ADSTAR, the Land Environment Working Group and the Land Forces International Land Defence Exposition.
- The company’s defence strategy combines proprietary IP, specialised product development capability and defence industry relationships to build larger and more enduring revenue streams.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Electro Optic Systems Holdings Limited (EOS) ORDINARY FULLY PAID |
Industrials |
$2,084 |
Notification regarding unquoted securities - EOS
|
31 Aug 2026 9:12AM |
$10.050 |
$9.400 |
fallen by
6.47%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$214 |
Trading Halt
|
31 Aug 2026 9:12AM |
$0.170 |
$0.120 |
fallen by
29.41%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Titomic Limited (ASX: TTT) in a trading halt on 31 August 2026.
- The trading halt was requested by Titomic pending an announcement about a proposed capital raising.
- The halt was made under ASX Listing Rule 17.1.
- The trading halt was to remain until the earlier of the market announcement being released or normal trading commencing on Wednesday, 2 September 2026.
- Titomic said it expected to release the capital raising announcement before trading resumed on 2 September 2026.
- Titomic stated it was not aware of any reason the trading halt should not be granted.
- The request letter was signed by Geoff Hollis, CFO and Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immutep Limited (IMM) ORDINARY FULLY PAID |
Health Care |
$34 |
Appendix 4E & 2026 Full Year Statutory Accounts
|
31 Aug 2026 9:12AM |
$0.050 |
$0.023 |
fallen by
54%
|
|
IMM - Price-sensitive ASX Announcement
Full Release
Key Points
- Appendix 4E relates to the year ended 30 June 2026 and was signed on 31 August 2026.
- The report is audited and includes the 2026 full year statutory accounts.
- Immutep is a clinical-stage biotechnology company developing LAG-3 related immunotherapies for cancer and autoimmune disease.
- The major operational setback in FY2026 was the discontinuation of the TACTI-004 Phase III first-line non-small cell lung cancer trial after an interim futility analysis in March 2026.
- Immutep commenced a root cause analysis and orderly wind-down of TACTI-004 following the IDMC recommendation.
- Other clinical programs continued to generate encouraging data, including INSIGHT-003, EFTISARC-NEO, TACTI-003, AIPAC-003 and the Phase I IMP761 study.
- IMP761, the company’s LAG-3 agonist antibody for autoimmune disease, reported favourable safety, tolerability and pharmacodynamic activity in Phase I.
- The FDA granted Orphan Drug Designation to efti for soft tissue sarcoma in April 2026.
- In January 2026 Immutep received a US$20 million upfront payment under its strategic licensing agreement with Dr Reddy’s Laboratories and repaid US$10 million in June 2026 after TACTI-004 was discontinued.
- Revenue from ordinary activities for FY2026 was A$14,556,923, compared with not applicable in FY2025.
- Other income fell 7.0% to A$9,612,077 from A$10,331,373.
- Total revenue and other income rose to A$24,169,000 from A$10,331,373, mainly due to recognised licensing revenue from Dr Reddy’s.
- Loss after tax attributable to owners increased 29.1% to A$79,304,563 from A$61,434,165.
- Research and development and intellectual property expenses increased to A$91.95 million from A$61.41 million, mainly due to higher clinical trial costs and a A$3.1 million impairment charge.
- Corporate administrative expenses increased to A$9.58 million from A$8.64 million.
- Interest income decreased to A$3.01 million from A$5.29 million due to lower cash and investment balances.
- The group recorded a A$1.87 million net loss on derivative financial instruments and a A$1.23 million net gain on foreign exchange in profit or loss.
- Other comprehensive income included a A$5.50 million foreign currency translation loss, compared with a A$14.38 million gain in FY2025.
- Cash, cash equivalents and term deposits at 30 June 2026 totalled about A$68.9 million, comprising A$63.7 million cash and cash equivalents and A$5.2 million term deposits.
- Net tangible asset backing per ordinary security was 4.1 cents, down from 9.3 cents in the previous corresponding period.
- Net assets at 30 June 2026 were A$61.53 million compared with A$143.64 million at 30 June 2025.
- Operating cash outflow for FY2026 was A$55.46 million.
- No dividend was paid or declared for FY2026 or FY2025.
- The company expects losses in FY2027 to be significantly lower than in FY2026 and says current cash resources should fund operations well into the first half of calendar 2028.
- The financial statements show no matter or circumstance arising after 30 June 2026 that significantly affected the group’s operations, results or state of affairs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
